ReviewMolecular cytogenetics2019
Head and neck cancer: searching for genomic and epigenetic biomarkers in body fluids - the state of art.
Review in Molecular cytogenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Epigenomic insights and computational advances in hematologic malignancies.Molecular cytogenetics · 2025Review
- Salivary Exosomal MicroRNA-486-5p and MicroRNA-10b-5p in Oral and Oropharyngeal Squamous Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2022Article
- Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.Non-coding RNA · 2022Review
- High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies.International journal of molecular sciences · 2022Review
- Cell-Free RNA as a Novel Biomarker for Response to Therapy in Head & Neck Cancer.Frontiers in oncology · 2022Article
- Gene Mutations in Circulating Tumour DNA as a Diagnostic and Prognostic Marker in Head and Neck Cancer-A Systematic Review.Biomedicines · 2021Review
- The Hidden Treasures of Preoperative Blood Assessment in Oral Cancer: A Potential Source of Biomarkers.Cancers · 2021Article
- The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer.Micromachines · 2021Article
- Salivary exosomal microRNAs as biomarkers for head and neck cancer detection-a literature review.Maxillofacial plastic and reconstructive surgery · 2021Review
- Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives.Cancers · 2021Review
- Oral cancer: changing the aim of the biopsy in the age of precision medicine. A review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2021Review
- Article
- Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.British journal of cancer · 2021Review
- An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance.Molecular biology reports · 2020Review
- Article
- Association of oral dysbiosis with oral cancer development.Oncology letters · 2020Review
- MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma.Cancer management and research · 2020Article
- Cytogenetics and Cytogenomics Evaluation in Cancer.International journal of molecular sciences · 2019Review
- Luciferase-Based Detection of Antibodies for the Diagnosis of HPV-Associated Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) affects multiple sites of the upper aerodigestive tract and exhibited high incidence and mortality worldwide, being frequently diagnosed at advanced stage. Early detection of HNSCC plays a crucial role in a successful therapy. In the last years, the survival rates of these tumors have not improved significantly due to the late diagnosis and the lack of precise disease biomarkers and targeted therapies. The introduction in the clinical practice of body fluids to detect and analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes provides a minimally or non-invasive method also called as liquid biopsy for diagnostic and prognostic biomarkers detection, representing a shift of paradigm in precision medicine through the revolution in the way to perform HNSCC diagnosis and to screen high risk population. Despite the use of body fluids being an emergent and up-to date issue to early diagnosis HNSCC and their recurrences, no strategy has yet proven to be consistently effective and able to be translated to clinical application in the routine clinical management of these patients. In this review we will discuss the recent discoveries using blood and saliva to identify biomarkers for the early detection and prognosis of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.